Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 610 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $145.55, for a total value of $88,785.50. Following the completion of the transaction, the chief financial officer now owns 76,468 shares of the company's stock, valued at approximately $11,129,917.40. The trade was a 0.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Michael Burkes Brophy also recently made the following trade(s):
- On Monday, March 31st, Michael Burkes Brophy sold 2,562 shares of Natera stock. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42.
- On Monday, March 17th, Michael Burkes Brophy sold 792 shares of Natera stock. The shares were sold at an average price of $146.04, for a total transaction of $115,663.68.
- On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The stock was sold at an average price of $176.88, for a total transaction of $7,694,633.76.
- On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $719,046.45.
- On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The stock was sold at an average price of $176.60, for a total value of $333,067.60.
- On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total value of $233,416.54.
- On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total value of $162,693.08.
Natera Price Performance
NASDAQ:NTRA opened at $148.56 on Thursday. Natera, Inc. has a one year low of $87.20 and a one year high of $183.00. The stock has a market cap of $20.08 billion, a PE ratio of -84.41 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a 50 day moving average price of $148.64 and a 200 day moving average price of $153.00.
Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Equities research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.
Institutional Trading of Natera
Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Natera by 7.7% in the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after acquiring an additional 879,463 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Natera by 134.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Natera by 43.7% during the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after purchasing an additional 2,036,396 shares during the period. Wellington Management Group LLP increased its position in shares of Natera by 15.7% during the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock worth $512,898,000 after purchasing an additional 439,778 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Natera by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock valued at $355,809,000 after buying an additional 142,201 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.
Analyst Ratings Changes
NTRA has been the topic of several recent research reports. Guggenheim upped their price objective on Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research report on Friday, January 17th. Barclays dropped their price target on shares of Natera from $200.00 to $160.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Morgan Stanley lifted their price objective on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Robert W. Baird increased their target price on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Finally, Royal Bank of Canada assumed coverage on Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target for the company. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, Natera currently has an average rating of "Moderate Buy" and a consensus price target of $175.76.
View Our Latest Research Report on NTRA
Natera Company Profile
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
